{"id":61377,"date":"2009-12-03T11:00:32","date_gmt":"2009-12-03T16:00:32","guid":{"rendered":"tag:www.hepatitis-central.com,2009:\/mt\/\/1.745"},"modified":"2009-12-03T11:03:15","modified_gmt":"2009-12-03T16:03:15","slug":"inovios-hcv-vaccine-trial-delivers-good-results","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/61377","title":{"rendered":"Inovio&#8217;s HCV Vaccine Trial Delivers Good Results"},"content":{"rendered":"<p>A small study of Inovio Biomedical&#8217;s Hepatitis C vaccine employing electric pulse technology yields encouraging safety data.<\/p>\n<p>Inovio Biomedical&#8217;s hepatitis C vaccine progresses<\/p>\n<p>Philadelphia Business Journal &#8211; by John George Staff Writer<br \/>\nMonday, November 30, 2009<\/p>\n<p>Inovio Biomedical Corp. said Monday its drug-development partner Tripep completed a phase-I clinical study of its hepatitis C DNA vaccine.<\/p>\n<p>Tripep of Sweden tested its vaccine, called ChronVac-C and delivered using Inovio&#8217;s electroporation technology, in 12 patients with positive results.<\/p>\n<p>Continue reading the entire article:<br \/>\n<a href=\"http:\/\/philadelphia.bizjournals.com\/philadelphia\/stories\/2009\/11\/30\/daily1.html\">http:\/\/philadelphia.bizjournals.com\/philadelphia\/stories\/2009\/11\/30\/daily1.html<\/a><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A small study of Inovio Biomedical&#8217;s Hepatitis C vaccine employing electric pulse technology yields encouraging safety data. Inovio Biomedical&#8217;s hepatitis C vaccine progresses Philadelphia Business Journal &#8211; by John George Staff Writer Monday, November 30, 2009 Inovio Biomedical Corp. said Monday its drug-development partner Tripep completed a phase-I clinical study of its hepatitis C DNA [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-61377","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/61377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=61377"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/61377\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=61377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=61377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=61377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}